Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 3×

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839

Graft-versus-leukemia reactions after bone marrow transplantation

Horowitz, M., Rp, G., Pm, S., Goldman, J. M., Kersey, J., Kolb, H., Rimm, A., Ringdén, O. T. H., Rozmán, C., & SPECK, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,769

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990

Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function

Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285

Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,081

An Immune Atlas of Clear Cell Renal Cell Carcinoma

Chevrier, S., Levine, J., Zanotelli, V. R., Siliņa, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,036

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

Sharma, M. D., Baban, B., Chandler, P., Hou, D., Singh, N., Yagita∥, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 791

DNA methylation controls Foxp3 gene expression

Polansky, J. K., Kretschmer, K., Freyer, J., Floess, S., Garbe, A. I., Baron, U., Olek, S., Hamann, A., von Boehmer, H., & Huehn, J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838105 · Cited by 784

Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes

Gallimore, A., Glithero, A., Godkin, A. J., Tissot, A. C., Plückthun, A., Elliott, T. J., Hengartner, H., & Zinkernagel, R. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1383 · Cited by 768

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675

Acute myeloid leukemia: Epidemiology and etiology

Deschler-Baier, B., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.22233 · Cited by 646

Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.

Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C. L., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y., McSweeney, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 595

CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation

Kim, H., & Leonard, W. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070109 · Cited by 590

Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation

Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Böttinger, E. P., Reid, S. P., Levy, D. E., & Bromberg, J. S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.259 · Cited by 564

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer

Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

Riches, J. C., DAVIES, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S. G., Ramsay, A. G., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 528

Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

Schumacher, K., Haensch, W., Röefzaad, C., & Schlag, P. M. (2001) · PubMed · Cited by 503

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

Kikushige, Y., Shima, T., Takayanagi, S., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T. T., Inagaki, Y., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.11.014 · Cited by 492

The TIGIT/CD226 Axis Regulates Human T Cell Function

Lozano, E., Dominguez‐Villar, M., Kuchroo, V. K., & Hafler, D. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103627 · Cited by 488

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 456

pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens

Hundal, J., Carreno, B. M., Petti, A. A., Linette, G. P., Griffith, O. L., Mardis, E. R., & Griffith, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0264-5 · Cited by 454

B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse

Pentcheva‐Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 446

PD-1 and its ligands in T-cell immunity

Keir, M. E., Francisco, L. M., & Sharpe, A. H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.012 · Cited by 444

Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus

Feng, Y., Arvey, A., Chinen, T., van der Veeken, J., Gasteiger, G., & Rudensky, A. Y. (2014) · Cell · doi:10.1016/j.cell.2014.07.031 · Cited by 422

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

Zhang, L., Gajewski, T. F., & Kline, J. P. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 417

Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells

Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036863 · Cited by 409

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Goodyear, O. C., Dennis, M., Jilani, N., Loke, J. C. T., Siddique, S., Ryan, G. B., Nunnick, J., Khanum, R., Raghavan, M., Cook, M. A., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377044 · Cited by 400

Vstm3 is a member of the CD28 family and an important modulator of T‐cell function

Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C. M., Howard, E. D., Chadwick, E. M., Johnston, J. V., Hammond, A. J., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 361

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

Mussai, F., Santo, C. D., Abu‐Dayyeh, I., Booth, S., Quek, L. S., McEwen-Smith, R. M., Qureshi, A., Dazzi, F., Vyas, P., & Cerundolo, V. (2013) · Blood · doi:10.1182/blood-2013-01-480129 · Cited by 346

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

Goodyear, O. C., Agathanggelou, A., Novitzky‐Basso, I., Siddique, S., McSkeane, T., Ryan, G. B., Vyas, P., Cavenagh, J. D., Stankovic, T., Moss, P. A. H., et al. (2010) · Blood · doi:10.1182/blood-2009-11-249474 · Cited by 340

Trial watch: IDO inhibitors in cancer therapy

Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 333

Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia

Szczepański, M. J., Szajnik, M. E., Czystowska, M., Mandapathil, M., Strauss, L., Welsh, A., Foon, K. A., Whiteside, T. L., & Boyiadzis, M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3010 · Cited by 309

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

Kong, Y., Zhu, L., Schell, T. D., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., George, M. R., Zeng, H., & Zheng, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2626 · Cited by 306

Regulatory T Cells: Differentiation and Function

Plitas, G., & Rudensky, A. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0193 · Cited by 298

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M. J., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275446 · Cited by 294

Programmed death 1 signaling on chronic myeloid leukemia–specific T cells results in T-cell exhaustion and disease progression

Mumprecht, S., Schürch, C. M., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 275

Reactivating the expression of methylation silenced genes in human cancer

Karpf, A. R., & Jones, D. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205602 · Cited by 264

Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma

Vesalainen, S., Lipponen, P., Talja, M. T., & Syrjänen, K. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)e0159-2 · Cited by 254

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

Scheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A. H., Mailänder, V., Baerwolf, S., Nagorsen, D., & Keilholz, U. (2002) · Blood · doi:10.1182/blood-2002-01-0163 · Cited by 248

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

Dieu, R. L., Taussig, D. C., Ramsay, A. G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A. M., Lister, T. A., & Gribben, J. G. (2009) · Blood · doi:10.1182/blood-2009-02-206946 · Cited by 245

The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer

Governa, V., Trella, E., Mele, V., Tornillo, L., Amicarella, F., Cremonesi, E., Muraro, M. G., Xu, H., Droeser, R. A., Däster, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2047 · Cited by 237

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230

Targeting regulatory T cells in tumors

Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

Sánchez-Abarca, L. I., Gutierrez-Cosío, S., Santamaría, C., Caballero‐Velázquez, T., Blanco, B., Herrero-Sánchez, C., Garcı́a, J. L., Carrancio, S., Hernández‐Campo, P. M., González, F. J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210393 · Cited by 226

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Üstün, C., Miller, J. S., Munn, D. H., Weisdorf, D. J., & Blazar, B. R. (2011) · Blood · doi:10.1182/blood-2011-07-365817 · Cited by 222

Wilms' tumour 1 (WT1) in development, homeostasis and disease

Hastie, N. D. (2017) · Development · doi:10.1242/dev.153163 · Cited by 216

Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches

Greiner, J., Schmitt, M. W., Li, L., Giannopoulos, K., Bosch, K., Schmitt, A., Döhner, K., Schlenk, R. F., Pollack, J. R., Döhner, H., et al. (2006) · Blood · doi:10.1182/blood-2006-01-023127 · Cited by 209

Elevated frequencies of CD4 + CD25 + CD127 lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia

Zhang, S., Han, Y., Wu, J., Kang, Y., Bi, L., Yan, Z., & Xu, X. (2010) · International Journal of Cancer · doi:10.1002/ijc.25791 · Cited by 201

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Pyzer, A. R., Stroopinsky, D., Rajabi, H. N., Washington, A. J., Tagde, A., Coll, M. D., Fung, J., Bryant, M. P., Cole, L., Palmer, K. A., et al. (2017) · Blood · doi:10.1182/blood-2016-07-730614 · Cited by 199

Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents

Héninger, E., Krueger, T. E. G., & Lang, J. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00029 · Cited by 194

Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection

Yamamoto, T., Price, D. A., Casazza, J. P., Ferrari, G., Nason, M., Chattopadhyay, P. K., Roederer, M., Emma Gostick, D., Katsikis, P. D., Douek, D. C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317297 · Cited by 193

Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 190

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients

Kozako, T., Yoshimitsu, M., Fujiwara, H., Masamoto, I., Horai, S., White, Y., Akimoto, M., Suzuki, S., Matsushita, K., Uozumi, K., et al. (2008) · Leukemia · doi:10.1038/leu.2008.272 · Cited by 181

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors

Berthon, C., Driss, V., Liu, J., Kuranda, K., Leleu, X. P., Jouy, N., Hétuin, D., & Quesnel, B. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0909-y · Cited by 175

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

Almstedt, M., Blagitko‐Dorfs, N., Duque‐Afonso, J., Karbach, J., Pfeifer, D., Jäger, E., & Lübbert, M. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.02.004 · Cited by 171

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

Rosenblatt, J. M., Stone, R. M., Uhl, L., Neuberg, D. S., Joyce, R., Levine, J. D., Arnason, J. E., McMasters, M., Luptakova, K., Jain, S. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1298 · Cited by 168

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality

Saha, A., Aoyama, K., Taylor, P. A., Koehn, B. H., Veenstra, R. G., Panoskaltsis‐Mortari, A., Munn, D. H., Murphy, W. J., Azuma, M., Yagita∥, H., et al. (2013) · Blood · doi:10.1182/blood-2013-05-500801 · Cited by 167

Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner

Al-Matary, Y. S., Botezatu, L., Opalka, B., Hönes, J. M., Lams, R. F., Thivakaran, A., Schütte, J., Koster, R., Lennartz, K., Schroeder, T. A., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143180 · Cited by 161

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

Kornblau, S. M., McCue, D. L., Singh, N., Chen, W., Estrov, Z. E., & Coombes, K. R. (2010) · Blood · doi:10.1182/blood-2010-01-262071 · Cited by 160

PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation

Kong, Y., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Zhu, L., Zeng, H., Schell, T. D., & Zheng, H. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.58 · Cited by 155

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

Schnorfeil, F. M., Lichtenegger, F. S., Emmerig, K., Schlueter, M., Neitz, J. S., Draenert, R., Hiddemann, W., & Subklewe, M. S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0189-2 · Cited by 152

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct

Matulonis, U. A., Dosiou, C., Freeman, G., Lamont, C., Mauch, P., Nadler, L. M., & Griffin, J. D. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.3.1126 · Cited by 150

CD160 and PD-1 Co-Expression on HIV-Specific CD8 T Cells Defines a Subset with Advanced Dysfunction

Peretz, Y., He, Z., Shi, Y., Yassine‐Diab, B., Goulet, J.-P., Bordi, R., Filali‐Mouhim, A., Loubert, J.-B., Far, M. E., Dupuy, F. P., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002840 · Cited by 150

Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression

Nunes, C., Wong, R., Mason, M. D., Fegan, C., Man, S., & Pepper, C. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2630 · Cited by 150

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

Zhou, Q., Bucher, C. M., Munger, M. E., Highfill, S. L., Tolar, J., Munn, D. H., Levine, B. L., Riddle, M. J., June, C. H., Vallera, D. A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208181 · Cited by 147

Increased population of CD4 + CD25 high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients

Wang, X., Zheng, J., Liu, J., Yao, J., He, Y., Li, X., Yu, J., Yang, J. X., Liu, Z., & Huang, S. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00537.x · Cited by 147

Immunity to WT1 in the animal model and in patients with acute myeloid leukemia

Gaiger, A., Reese, V. A., Disis, M. L., & Cheever, M. A. (2000) · Blood · doi:10.1182/blood.v96.4.1480 · Cited by 142

Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways

Buggins, A. G. S., Milojković, D., Arno, M. J., Lea, N. C., Mufti, G. J., Thomas, N. S. B., & Hirst, W. J. R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.6021 · Cited by 141

Dual biological effects of the cytokines interleukin-10 and interferon-γ

Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

Kittang, A. O., Kordasti, S. Y., Sand, K. E., Costantini, B., Kramer, A. M., Abellan, P. P., Seidl, T., Rye, K. P., Hagen, K. M., Kulasekararaj, A. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062208 · Cited by 132

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, L. H., Söderlund, S., Svensson, E., Mustjoki, S. M., Bengtsson, M., Simonsson, B., Olsson‐Strömberg, U., & Loskog, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055818 · Cited by 129

CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells

Pistillo, M. P. (2002) · Blood · doi:10.1182/blood-2002-06-1668 · Cited by 127

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L., Snyder, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.036 · Cited by 126

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

Costantini, B., Kordasti, S. Y., Kulasekararaj, A. G., Jiang, J., Seidl, T., Abellan, P. P., Mohamedali, A., Thomas, N. S. B., Farzaneh, F., & Mufti, G. J. (2012) · Haematologica · doi:10.3324/haematol.2012.074823 · Cited by 124

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

Chen, X., Liu, S., Wang, L., Zhang, W., Ji, Y., & Ma, X. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5689 · Cited by 122

The emerging role of immune checkpoint based approaches in AML and MDS

Boddu, P. C., Kantarjian, H. M., Garcia‐Manero, G., Allison, J. P., Sharma, P., & Daver, N. G. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1344905 · Cited by 120

Humoral immune responses against Wilms tumor gene WT1product in patients with hematopoietic malignancies

Elisseeva, O. A., Oka, Y., Tsuboi, A., Ogata, K., Wu, F., Kim, E. H., Soma, T., Tamaki, H., Kawakami, M., Oji, Y., et al. (2002) · Blood · doi:10.1182/blood.v99.9.3272 · Cited by 119

Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses

Wang, L., Mei, Z.-Y., Zhou, J., Yao, Y., Li, Y.-H., Xu, Y., Li, J., Gao, X., Zhou, M., Jiang, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062924 · Cited by 113

Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia

Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., Bertaina, V., Mastronuzzi, A., Gaspari, S., Zecca, M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1504 · Cited by 110

Epigenetic Changes in the Myelodysplastic Syndrome

Issa, J. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.007 · Cited by 110

Interferon‐induced programmed death‐ligand 1 ( PD ‐ L 1/ B 7‐ H 1) expression increases on human acute myeloid leukemia blast cells during treatment

Krönig, H., Kremmler, L., Haller, B., Englert, C., Peschel, C., Andreesen, R., & Blank, C. U. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12228 · Cited by 110

Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach

Johanns, T. M., Ward, J. P., Miller, C. A., Wilson, C., Kobayashi, D. K., Bender, D. E., Fu, Y., Alexandrov, A., Mardis, E. R., Artyomov, M. N., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0156 · Cited by 106

Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies

Stasi, A. D., Jiménez, A., Minagawa, K., Al‐Obaidi, M., & Rezvani, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00036 · Cited by 103

Augmentation of naive, Th1 and Th2 effector CD4 Responses by IL-6, IL-1 and TNF

Joseph, S. B., Miner, K. T., & Croft, M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01 · Cited by 100

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ

Corm, S., Berthon, C., Imbenotte, M., Biggio, V., Lhermitte, M., Dupont, C., Briche, I., & Quesnel, B. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.014 · Cited by 97

Augmented expression of programmed death‐1 in both neoplastic and non‐neoplastic CD4+ T‐cells in adult T‐cell leukemia/lymphoma

Shimauchi, T., Kabashima, K., Nakashima, D., Sugita, K., Yamada, Y., Hino, R., & TOKURA, Y. (2007) · International Journal of Cancer · doi:10.1002/ijc.23042 · Cited by 94

Expression of checkpoint molecules on myeloid-derived suppressor cells

Ballbach, M., Dannert, A., Singh, A., Siegmund, D. M., Handgretinger, R., Piali, L., Rieber, N. P., & Hartl, D. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.10.001 · Cited by 91

Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia

Tan, J., Chen, S., Lu, Y., Yao, D., Xu, L., Zhang, Y., Yang, L., Chen, J., Lai, J., Yu, Z. H., et al. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.05.11 · Cited by 89

Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells

Ersvær, E., Liseth, K., Skavland, J., Gjertsen, B. T., & Bruserud, Ø. (2010) · BMC Immunology · doi:10.1186/1471-2172-11-38 · Cited by 88

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

Gang, A. O., Frøsig, T. M., Brimnes, M. K., Lyngaa, R., Treppendahl, M. B., Grønbæk, K., Dufva, I. H., Straten, P. T., & Hadrup, S. R. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.14 · Cited by 86

CD8 + T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients

Wang, M., Bu, J., Zhou, M., Sido, J. M., Lin, Y., Liu, G., Lin, Q., Xu, X., Leavenworth, J. W., & Shen, E. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.021 · Cited by 83

Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia

Orleans‐Lindsay, J. K., Barber, L. D., Prentice, H. G., & Lowdell, M. W. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01692.x · Cited by 81

Tumor Secretion of CCL22 Activates Intratumoral Treg Infiltration and Is Independent Prognostic Predictor of Breast Cancer

Li, Y.-Q., Liu, F., Zhang, X.-M., Guo, X.-J., Ren, M.-J., & Fu, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076379 · Cited by 81

Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia

Panoskaltsis, N., Reid, C. D. L., & Knight, S. C. (2003) · Leukemia · doi:10.1038/sj.leu.2402835 · Cited by 78

Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: Evidence for systemic activation of the T cell compartment

den Hove, L. E. V., Vandenberghe, P., Gool, S. W. V., Ceuppens, J. L., Demuynck, H., Verhoef, G. E. G., & Boogaerts, M. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00152-5 · Cited by 73

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

Kanakry, C. G., Hess, A. D., Gocke, C. D., Thoburn, C. J., Kos, F. J., Meyer, C. F., Briel, J., Luznik, L., Smith, B. D., Levitsky, H. I., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277939 · Cited by 67

Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.

Li, C., Chen, X., Xiao, Y., Zhu, Y., Ma, C., Xia, R., Ma, J., Gu, C., Ye, L., & Wu, D. (2014) · PubMed Central · Cited by 58

Myeloid-derived suppressor cells in B cell malignancies

Yazdani, Y., Mohammadnia‐Afrouzi, M., Yousefi, M., Anvari, E., Ghalamfarsa, G., Hassannia, H., Sadreddini, S., & Jadidi‐Niaragh, F. (2015) · Tumor Biology · doi:10.1007/s13277-015-4004-z · Cited by 58

CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system

Zhong, R., Loken, M. R., Lane, T. A., & Ball, E. (2006) · Cytotherapy · doi:10.1080/14653240500499507 · Cited by 57

Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia

Wendelbo, �., Nesthus, I., Sjo, M., Rye, K. P., Ernst, P., & Bruserud, �. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0505-0 · Cited by 55

Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia

Mansour, I., Zayed, R. A., Said, F., & Soliman, L. (2016) · Hematology · doi:10.1080/10245332.2015.1106814 · Cited by 51

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells

Rey, J., Fauriat, C., Kochbati, E., Orlanducci, F., Charbonnier, A., D’Incan, E., André, P., Romagné, F., Barbarat, B., Vey, N., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00064 · Cited by 51

Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage

Re, F., Arpinati, M., Testoni, N., Ricci, P., Terragna, C., PREDA, P., Ruggeri, D., Senese, B., Chirumbolo, G., Martelli, V., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00768-8 · Cited by 49

Myeloid leukemia cells with a B7‐2+ subpopulation provoke Th‐cell responses and become immuno‐suppressive through the modulation of B7 ligands

Dölen, Y., & Esendağlı, G. (2012) · European Journal of Immunology · doi:10.1002/eji.201242814 · Cited by 48

Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia

LaBelle, J. L., Hanke, C. A., Blazar, B. R., & Truitt, R. L. (2002) · Blood · doi:10.1182/blood.v99.6.2146 · Cited by 48

High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

Mabuchi, R., Hara, T., Matsumoto, T., Shibata, Y., Nakamura, N., Nakamura, H., Kitagawa, J., Kanemura, N., Goto, N., Shimizu, M., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1041388 · Cited by 47

Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia

Fozza, C., Corda, G., Barraqueddu, F., Virdis, P., Contini, S., Galleu, A., Isoni, A., Dore, F., Angelucci, E., & Longinotti, M. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.06.007 · Cited by 44

Diversity of Clonal T Cell Proliferation Is Mediated by Differential Expression of CD152 (CTLA-4) on the Cell Surface of Activated Individual T Lymphocytes

Maszyna, F., Hoff, H., Kunkel, D., Radbruch, A., & Brunner-Weinzierl, M. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3459 · Cited by 44

Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics

Fukuno, K., Hara, T., Tsurumi, H., Shibata, Y., Mabuchi, R., Nakamura, N., Kitagawa, J., Shimizu, M., Ito, H., Saito, K., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953150 · Cited by 44

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia

Giallongo, C., Parrinello, N. L., Brundo, M. V., Raccuia, S. A., Rosa, M. D., Cava, P. L., & Tibullo, D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00107 · Cited by 42

CTLA‐4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis

Laurent, S., Palmisano, G. L., Martelli, A. M., Kato, T., Tazzari, P. L., Pierri, I., Clavio, M., Dozin, B., Balbi, G., Megna, M., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06472.x · Cited by 41

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia

Gassner, F. J., Zaborsky, N., Neureiter, D., Huemer, M., Melchardt, T., Egle, A., Rebhandl, S., Catakovic, K., Hartmann, T. N., Greil, R., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.098459 · Cited by 40

Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution

Vídriales, M., Orfao, A., López-Berges, M. C., González, M., Hernández‐Rivas, J. M., Ciudad, J., López, A., Moro, M., Martínez, M. D. L., & Miguel, J. F. S. (1993) · Annals of Hematology · doi:10.1007/bf01715050 · Cited by 39

Targeting immune checkpoints in lymphoma

Ansell, S. M. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000158 · Cited by 39

Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia

Ismail, M. M., & Abdulateef, N. A. B. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2153-5 · Cited by 38

Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review

Fisher, S. A., Lamikanra, A., Doree, C. J., Gration, B., Tsang, P., Danby, R., & Roberts, D. J. (2017) · British Journal of Haematology · doi:10.1111/bjh.14433 · Cited by 36

Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML

Lichtenegger, F. S., Lorenz, R., Gellhaus, K., Hiddemann, W., Beck, B., & Subklewe, M. S. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.05.014 · Cited by 32

The in situ local immune response, tumour senescence and proliferation in colorectal cancer

Roxburgh, C. S. D., Richards, C. H., Macdonald, A. I., Powell, A. G. M. T., McGlynn, L. M., McMillan, D. C., Horgan, P. G., Edwards, J., & Shiels, P. G. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.556 · Cited by 29

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation

Soiffer, R. J., Davids, M. S., & Chen, Y. (2018) · Blood · doi:10.1182/blood-2017-10-752154 · Cited by 26

Beneficial role of increased FOXP 3+ regulatory T‐cells in acute myeloid leukaemia therapy response

Menter, T., Kuzmanic, B., Bucher, C. M., Medinger, M., Halter, J. P., Dirnhofer, S., & Tzankov, A. (2017) · British Journal of Haematology · doi:10.1111/bjh.14819 · Cited by 9

Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia

Tang, L., Wu, J., Li, C.-G., Jiang, H., Xu, M., Du, M., Yin, Z., Mei, H., & Hu, Y. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3003 · Cited by 140

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Abbas, H. A., Hao, D., Tomczak, K. J., Barrodia, P., Im, J. S., Reville, P. K., Alaniz, Z., Wang, W., Wang, R., Wang, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26282-z · Cited by 130

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia

Lamble, A. J., Kosaka, Y., Laderas, T., Maffit, A., Kaempf, A. J., Brady, L., Wang, W., Long, N., Saultz, J. N., Mori, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916206117 · Cited by 98

Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy

Khaldoyanidi, S. K., Nagorsen, D., Stein, A. S., Ossenkoppele, G. J., & Subklewe, M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00475 · Cited by 108

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 102

Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment

Serroukh, Y. I. M., Hébert, J., Busque, L., Mercier, F., Rudd, C. E., Assouline, S. E., Lachance, S., & Delisle, J. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100991 · Cited by 30

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Wu, Y., Li, Y., Gao, Y., Zhang, P., Jing, Q., Zhang, Y., Jin, W., Wang, Y., Du, J., & Wu, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116132 · Cited by 35

Unlocking the Power of Immune Microenvironment in AML Therapy: Current Insight and Future Prospects

Kelesoglu, N., & Arğa, K. Y. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_230 · Cited by 3

DEFINING THE IMMUNE MICROENVIRONMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Lind, E. F., Lamble, A. J., & Kosaka, Y. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.196.supp.211.20

Immunotherapy in Acute Myeloid Leukemia: Where We Stand

Isidori, A., Cerchione, C., Daver, N. G., Dinardo, C. D., Garcia‐Manero, G., Konopleva, M. Y., Jabbour, E. J., Ravandi, F., Kadia, T. M., Burguera, A. D. L. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656218 · Cited by 95